Carole Ho

What if we could identify who would respond to a new medicine before starting treatment?

Share This Talk

Have a suggestion for The Hive?
Submit a Nomination Today

About Carole Ho

Carole Ho is the Chief Medical Officer of Denali Therapeutics. Carole’s curiosity of how the brain functions in health and disease guided her career from clinical neurologist to bench neuroscientist at Harvard and Stanford, after which she moved on to Genentech as an industry drug developer. She has a passion for innovative approaches to tailoring therapies for those that are most likely to respond. She has provided leadership for a landmark prevention trial in familial inherited Alzheimer's Disease in an extended Colombian family and has successfully translated genetic discoveries to therapies in the clinic at Genentech. 

Find out more

About This Idea

Neurodegenerative diseases are the largest medical challenges of our time, and Denali Therapeutics is dedicated to defeating them through rigorous therapeutic discovery and development. Denali is founded on the collaboration of leading scientists, industry experts and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients. Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases.

Find out more

More Talks from the Hive

These talks are all a part of special session at TEDMED, called "Audacious" where we invite our innovators to take the stage and share the central idea they are working on, in short 2-minute talks. These talks are creatively grouped by 4 mini-segments, that serves as a creative link between each talk. To find out more visit The Hive page.